Mayo Clinic | Strategic Alliance Partners

July 16, 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on data for iptacopan in PNH after switching anti-C5 therapy.

July 14, 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

July 14, 2025

Mayo Clinic researchers have discovered a key reason some patients with cancer relapse after receiving CAR T-cell therapy.

July 09, 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the implications of the FDA approval of Iptacopan for PNH.

July 02, 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

July 02, 2025

Cholangiocarcinoma care begins with an evaluation by a multidisciplinary team. Mayo Clinic team members work together to review cases as a tumor board.

June 24, 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

June 22, 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

June 11, 2025

The Mayo Clinic's new facility will house the first carbon ion therapy program in the Western Hemisphere.

June 04, 2025

Recent research at Mayo Clinic evaluated thyroid cancer risk in men and women.

May 26, 2025

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

May 22, 2025

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

May 01, 2025

April 26, 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

April 07, 2025

Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.

April 02, 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

March 31, 2025

A Mayo Clinic study showed that KRAS circulating tumor DNA strongly indicates a higher risk of pancreatic cancer spread and worse survival rates.

March 30, 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

March 25, 2025

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

March 23, 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.